Connecting genomic alterations to cancer biology with proteomics: The NCI clinical proteomic tumor analysis consortium

Matthew J. Ellis, Michael Gillette, Steven A. Carr, Amanda G. Paulovich, Richard D. Smith, Karin K. Rodland, R. Reid Townsend, Christopher Kinsinger, Mehdi Mesri, Henry Rodriguez, Daniel C. Liebler

Research output: Contribution to journalArticlepeer-review

127 Scopus citations

Abstract

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods.

Original languageEnglish
Pages (from-to)1108-1112
Number of pages5
JournalCancer discovery
Volume3
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Dive into the research topics of 'Connecting genomic alterations to cancer biology with proteomics: The NCI clinical proteomic tumor analysis consortium'. Together they form a unique fingerprint.

Cite this